AbbVie: Maintaining My Strong Buy Rating After Label Expansion (NYSE:ABBV)
· seekingalpha.com
AbbVie (ABBV) outlook: Skyrizi & Rinvoq drive growth as Humira fades. Read the full analysis here.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...